Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Dedicated RMB 3.5 Billion For TCM Development In 2008

This article was originally published in PharmAsia News

Executive Summary

China's National Development and Reform Commission, Ministry of Finance and Ministry of Science and Technology allocated funds of more than RMB 3.5 billion ($512.36 million) in 2008 to support traditional Chinese medicine development. The unprecedented financial support in terms of strength and scope covers health care, education, research, culture and infrastructure establishment of TCM hospitals. Of the amount, RMB 31 million ($4.53 million) came from central finance for an innovative program to publicize and popularize TCM knowledge nationwide. Recently, NDRC and the State Administration of Traditional Chinese Medicine jointly identified 16 key TCM clinical research areas for development. With investment of more than RMB 4 billion ($585 million), the project is scheduled to begin in 2009. The increased funding seeks to accelerate changes in TCM fundamentals and innovation. (Click here for more - Chinese Language)

You may also be interested in...

China’s 2008 Top 10 TCM News

China's State Administration of Traditional Chinese Medicine has picked the top 10 TCM news events of 2008

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts